In the published article, the Conflict of interest statement was incorrect. The correct Conflict of interest statement appears below:
Conflict of interest
“The author FS has received research support from Mastelli for work on polydeoxyribonucleotide. Authors FS, AB and DA are co-inventors on a patent describing therapeutic polydeoxyribonucleotide activity in chronic intestinal disease. Author LM, FS and AB are co-inventor on a patent describing therapeutic polydeoxyribonucleotide activity in testicular injury by torsion.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest”.
The authors apologize for this error and state that this does not change the scientific conclusion of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
adenosine receptors, inflammation, neurogenesis, polydeoxyribonucleotide, spinal cord injury
Citation
Irrera N, Arcoraci V, Mannino F, Vermiglio G, Pallio G, Minutoli L, Bagnato G, Anastasi GP, Mazzon E, Bramanti P, Squadrito F, Altavilla D and Bitto A (2022) Corrigendum: Activation of A2A receptor by PDRN reduces neuronal damage and stimulates WNT/β-catenin driven neurogenesis in spinal cord injury. Front. Pharmacol. 13:1073726. doi: 10.3389/fphar.2022.1073726
Received
18 October 2022
Accepted
03 November 2022
Published
03 November 2022
Approved by
Frontiers Editorial Office, Frontiers Media SA, Switzerland
Volume
13 - 2022
Updates
Copyright
© 2022 Irrera, Arcoraci, Mannino, Vermiglio, Pallio, Minutoli, Bagnato, Anastasi, Mazzon, Bramanti, Squadrito, Altavilla and Bitto.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Francesco Squadrito, fsquadrito@unime.it
This article was submitted to Neuropharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.